News · 26 weeks35+50%
2026-04-192026-10-11
Mix1390d
- SEC Filings10(77%)
- Other3(23%)
Latest news
25 items- SECSEC Form DEF 14A filed by GT Biopharma Inc.DEF 14A - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form S-1 filed by GT Biopharma Inc.S-1 - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form PRE 14A filed by GT Biopharma Inc.PRE 14A - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form D filed by GT Biopharma Inc.D - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form 8-K filed by GT Biopharma Inc.8-K - GT Biopharma, Inc. (0000109657) (Filer)
- SECGT Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- PRGT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple MyelomaFDA clearance of a new IND for GTB-5550 in multiple myeloma (MM) under an investigator sponsored trial (IST) protocol Initiation of Phase 1 trial in MM patients contingent upon timing and receipt of non-dilutive grant funding Phase 1 dose escalation basket trial with GTB-5550 in solid tumor patients continues to actively enroll, with an update anticipated in Q4 2026 Unaudited proforma cash balance as of September 15, 2026 of approximately $11 million anticipated to provide sufficient cash runway into Q3 2027 SAN FRANCISCO, CALIFORNIA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innov
- SECGT Biopharma Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- PRGT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026SAN FRANCISCO, CALIFORNIA, Sept. 11, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Company") (NASDAQ:GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, will host a live company presentation on the development of the TriKE® platform for cancer treatment today, September 11, 2026, at 2:00 p.m. Eastern Time. The webinar will feature Michael Breen, Executive Chairman and Chief Executive Officer of GT Biopharma, and Dr. Jeffrey Miller, MD1, Consulting Senior Medical Director, who will discuss clinical progress in blood cancers and solid tumors, insights from incre
- SECGT Biopharma Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- SECGT Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- SECSEC Form 10-Q filed by GT Biopharma Inc.10-Q - GT Biopharma, Inc. (0000109657) (Filer)
- PRGT Biopharma Reports Second Quarter 2026 Financial ResultsPhase 1 trial evaluating GTB-3650 TriKE® remains ongoing, with an update anticipated in 2H 2026 Phase 1 basket trial evaluating GTB-5550 TriKE® in multiple solid tumor types known to express B7-H3 initiated May 2026 with an update anticipated in 2H 2026 as enrollment progresses through dose escalation cohorts Increased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins, supporting the anticipation of multiple new development candidates moving towards pre-IND development in 2027 Cash balance as of June 30, 2026 of approximately $5.1 million anticipated to provide sufficient cash runway through Q4 202
- PRA Clinical-Stage Cancer Company Is Putting AI to Work at the Bench, Designing Its Next Generation of Tumor-Targeting DrugsIssued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) said it has integrated AI-based tools across the discovery and engineering of its tumor-targeting NK cell engagers and multi-domain proteins, efficiency gains the company expects to push multiple new development candidates into pre-IND development in 2027.SAN FRANCISCO, July 6, 2026 /CNW/ -- American News Group News Commentary, Artificial intelligence has become a fixture in biotech marketing, but the more consequential question is where it is actually used: in the slide deck, or at the bench. GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company, says it is applying AI to the latter, embedding AI-bas
- SECSEC Form DEF 14A filed by GT Biopharma Inc.DEF 14A - GT Biopharma, Inc. (0000109657) (Filer)
- PRA Clinical-Stage Cancer Company Is Putting AI to Work Designing Its Next Generation of Tumor-Targeting DrugsIssued on behalf of GT Biopharma, Inc.GT Biopharma, Inc. (NASDAQ:GTBP) says newly implemented AI-based tools are accelerating its drug discovery and engineering, with multiple new development candidates expected to move into pre-IND development in 2027 and potential indications expanding beyond oncology.USA News Group News CommentaryNEW YORK, June 30, 2026 /CNW/ -- Drug discovery has long been a slow, expensive process of trial and error, and for a small clinical-stage company, every wasted experiment is capital it can scarcely afford. That is the backdrop for a recent update from GT Biopharma, Inc. (NASDAQ:GTBP), a clinical-stage immuno-oncology company built around its proprietary natural
- SECSEC Form PRE 14A filed by GT Biopharma Inc.PRE 14A - GT Biopharma, Inc. (0000109657) (Filer)
- SECGT Biopharma Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- PRAfter CAR-T, the Next Frontier in Cancer Immunotherapy May Belong to a Different Immune CellIssued on behalf of GT Biopharma, Inc. Natural killer cells were long overshadowed by T-cell therapies. Now a growing field is trying to unleash them — with the promise of off-the-shelf, lower-toxicity treatments for cancers that have resisted everything else. SAN FRANCISCO, June 12, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary — The last decade of cancer immunotherapy was written largely in the language of T cells. Checkpoint inhibitors unleashed them; CAR-T therapies re-engineered them and produced some of the most dramatic remissions modern medicine has ever recorded. But T-cell therapies also carry hard limits: they can be brutally toxic, they are often manufactured one p
- PRThree Cancer Drugs Have Reached the Clinic: Inside GT Biopharma's TriKE BetIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP) A clinical-stage immuno-oncology company has moved three drug candidates into human testing over time --- and most recently expanded into solid tumors --- while carrying a market value that remains modest relative to many clinical-stage oncology peers. SAN FRANCISCO, June 08, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary -- Most clinical-stage cancer companies with three drugs that have reached human trials carry valuations in the hundreds of millions of dollars, or more. GT Biopharma, Inc. (NASDAQ:GTBP) has now advanced three TriKE® candidates into the clinic over time --- GTB-3550, GTB-3650 and GTB-5550 --- though its curr
- PRA Third Cancer Drug Just Entered the Clinic at an Under-$20-Million CompanyEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)SAN FRANCISCO, June 2, 2026 /CNW/ -- Most clinical-stage cancer companies with three drugs dosing patients in human trials carry valuations in the hundreds of millions, or more. GT Biopharma, Inc. (NASDAQ:GTBP) recently put its third drug into the clinic — and the entire company has at times been valued at a small fraction of that. The gap between what the company is doing in the lab and what the market is paying for it is the whole story here, and a milestone reached in mid-May has brought it into sharp focus.
- PRGT Biopharma Provides Update on Pipeline Discovery Activities from Newly Implemented AI-Based Technological InitiativesIncreased integration of artificial intelligence–based tools across the discovery and engineering of tumor-targeting engagers and multi-domain proteins to accelerate development while reducing developmental costs Reduces reliance on trial-and-error experimentation, shortens development timelines, and increases likelihood that pipeline candidates demonstrate robust binding and functional activity suitable for translational advancement GT Biopharma anticipates multiple new development candidates moving into pre-IND development in 2027, with potential targets and indications expanding beyond oncology SAN FRANCISCO, CALIFORNIA, June 01, 2026 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the "Comp
- PRThe $13 Million Company Teaching the Immune System to Hunt CancerIssued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep
- SECGT Biopharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits8-K - GT Biopharma, Inc. (0000109657) (Filer)
- PRThree TriKE Candidates In Clinic As NK Cell Engager Field ReorganizesEquity Insider News CommentaryIssued on behalf of GT Biopharma, Inc.Companies mentioned: GT Biopharma, Inc. (NASDAQ:GTBP), Fate Therapeutics, Inc. (NASDAQ:FATE), Nkarta, Inc. (NASDAQ:NKTX), ImmunityBio, Inc. (NASDAQ:IBRX), INmune Bio, Inc. (NASDAQ:INMB)SAN FRANCISCO, May 19, 2026 /CNW/ -- The case for natural killer cell-based immunotherapy has been one of the longer-running theses in clinical oncology. NK cells sit on the body's first line of defense against foreign invaders, can be deployed as off-the-shelf therapeutics derived from donor cells or pluripotent stem cells, and have demonstrated meaningfully lower rates of cytokine release syndrome and graft-versus-host disease than the autol
GTBP FAQ
6 questionsWhat does GT Biopharma Inc. do?
GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. The company develops various immuno-oncology product candidates, including GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and other CD33+...Where does GTBP stock trade?
GT Biopharma Inc. (GTBP) is listed on NASDAQ.What sector and industry is GTBP in?
GT Biopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about GTBP?
GT Biopharma Inc. has had 1 recent analyst action on file. The most recent action was from ROTH MKM: Buy with a $1100.00 price target on 2024-12-02. Recent price targets cluster around $1100.00.What companies are similar to GTBP?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare GTBP side-by-side with any of them on Quantisnow.How can I track GTBP on Quantisnow?
Quantisnow aggregates GT Biopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow GTBP to receive live email and push alerts on every new disclosure.